Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Moodys
McKinsey
AstraZeneca
Medtronic
Harvard Business School

Last Updated: November 17, 2019

DrugPatentWatch Database Preview

DIPRIVAN Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Diprivan, and when can generic versions of Diprivan launch?

Diprivan is a drug marketed by Fresenius Kabi Usa and is included in one NDA. There is one patent protecting this drug.

This drug has one patent family member in one country.

The generic ingredient in DIPRIVAN is propofol. There are twelve drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the propofol profile page.

Drug patent expirations by year for DIPRIVAN
Drug Prices for DIPRIVAN

See drug prices for DIPRIVAN

Recent Clinical Trials for DIPRIVAN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Keith M. Vogt, MD, PhDPhase 4
University of UtahPhase 2/Phase 3
NHS LothianPhase 3

See all DIPRIVAN clinical trials

Recent Litigation for DIPRIVAN

Identify potential future generic entrants

District Court Litigation
Case NameDate
FRESENIUS KABI USA LLC v. BIOQ PHARMA INC.2018-03-01
Fresenius Kabi USA, LLC v. B. Braun Medical Inc.2016-04-11
Fresenius Kabi USA LLC v. Claris Lifesciences Ltd.2014-12-19

See all DIPRIVAN litigation

PTAB Litigation
PetitionerDate
J Kyle, Bass2015-11-25
Dr. Reddy's Laboratories, Inc.2015-02-06

See all DIPRIVAN litigation

Pharmacology for DIPRIVAN
Drug ClassGeneral Anesthetic
Physiological EffectGeneral Anesthesia
Synonyms for DIPRIVAN
2, 6-Diisopropylphenol
2,6 Diisopropylphenol
2,6-Bis(1-methylethyl)phenol
2,6-bis(Isopropyl)phenol
2,6-bis(methylethyl)phenol
2,6-bis(propan-2-yl)phenol
2,6-di isopropyl phenol
2,6-di(propan-2-yl)phenol
2,6-Diisopropyl phenol
2,6-diisopropyl-phenol
2,6-DIISOPROPYLPHENOL
2,6-Diisopropylphenol, >=97%
2,6-Diisopropylphenol, 97%
2,6-Diisopropylphenol, analytical standard
2,6-DIISOPROPYLPHENOL; PROPOFOL
2078-54-8
28449-97-0
3f33
3p50
4-06-00-03435 (Beilstein Handbook Reference)
50356-15-5
A814898
AB00513968
AB00513968_08
AB00513968-07
AC-2038
AC1L1J9Y
AC1Q1OUI
ACMC-1CPLW
AI3-26295
AJ-24593
AKOS009159417
AM90311
Ampofol
AN-3506
ANW-24224
Aquafo
Aquafol
AS-13299
BCP02920
BCP0726000298
BDBM50058046
BIDD:GT0436
Biomol-NT_000248
BPBio1_000950
BPBio1_000969
BRD-K82255054-001-03-5
BRD-K82255054-001-08-4
BRN 1866484
BSPBio_000862
C07523
C12H18O
CAS-2078-54-8
CCG-204529
CCRIS 9000
CHEBI:44915
CHEMBL526
CJ-04649
CP0141
CPD000059151
CS-W020057
CTK3J0557
D00549
D0617
D126608
DB00818
DDS-04F
Diisopropylphenol
Diisopropylphenol (Related)
Dipravan
Diprifusor
Diprivan (TN)
Diprivan 10
Diprivan Injectable emulsion
Diprofol
Disoprivan
Disoprofol
DSSTox_CID_3523
DSSTox_GSID_23523
DSSTox_RID_77063
DTXSID6023523
EINECS 218-206-6
EU-0100437
Fresofol
FT-0610672
ghl.PD_Mitscher_leg0.558
GTPL5464
H835
HMS1570L04
HMS2089O21
HMS2094E17
HMS2097L04
HMS2231E16
HMS3259E03
HMS3261G16
HMS3369I16
HMS3714L04
HSDB 7123
ICI 35,868
ICI 35868
ICI-35,868
ICI-35868
InChI=1/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H
Ivofol
Jsp004266
KS-00000MQ0
KSC490K5P
Lopac-D126608
Lopac0_000437
LP00437
LS-996
MCULE-1903292305
MFCD00008885
MFCD00008885 (98%)
MLS-0318084
MLS-0318084.P017
MLS001066348
MLS001335999
MLS002454360
NC00449
NCGC00015389-01
NCGC00015389-02
NCGC00015389-03
NCGC00015389-04
NCGC00015389-05
NCGC00015389-06
NCGC00015389-07
NCGC00015389-08
NCGC00015389-09
NCGC00015389-10
NCGC00015389-11
NCGC00015389-14
NCGC00091538-01
NCGC00091538-02
NCGC00091538-03
NCGC00091538-04
NCGC00091538-05
NCGC00091538-06
NCGC00257228-01
NCGC00260670-01
NCGC00261122-01
NSC 5105
NSC-5105
NSC-758909
NSC5105
NSC758909
OLBCVFGFOZPWHH-UHFFFAOYSA-N
PFL
Pharmakon1600-01505022
Phenol, 2, 6-bis(1-methylethyl)-
Phenol, 2,6-bis(1-methylethyl)-
Phenol, 2,6-diisopropyl-
Phenol,6-bis(1-methylethyl)-
Phenol,6-diisopropyl-
Pofol
Prestwick0_000931
Prestwick1_000931
Prestwick2_000931
Prestwick3_000931
propofol
Propofol (Diprivan)
Propofol (JAN/USAN/INN)
Propofol [USAN:INN:BAN]
Propofol [USAN:USP:INN:BAN]
Propofol 1.0 mg/ml in Methanol
Propofol for peak identification, European Pharmacopoeia (EP) Reference Standard
Propofol IDD-D
Propofol solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material
Propofol-Lipuro
Propofol, British Pharmacopoeia (BP) Reference Standard
Propofol, European Pharmacopoeia (EP) Reference Standard
Propofol, Pharmaceutical Secondary Standard; Certified Reference Material
Propofol, United States Pharmacopeia (USP) Reference Standard
Propofolum
Propofolum [Latin]
Propovan
Propoven
Q-201631
Rapinovet
Recofol
RP23984
RTR-009757
S01-0189
SAM002264610
SC-18796
SCHEMBL36245
SMR000059151
SPBio_003031
SPECTRUM1505022
SR-01000075468
SR-01000075468-1
SR-01000075468-4
SR-01000075468-6
ST2415947
ST50405911
SY013479
Tox21_110134
Tox21_110134_1
Tox21_201371
Tox21_303225
Tox21_500437
TR-009757
TRA0038441
UNII-YI7VU623SF
VZ22957
YI7VU623SF
Z1245735300
ZB015550
ZD-0859
ZINC968303
Paragraph IV (Patent) Challenges for DIPRIVAN
Tradename Dosage Ingredient NDA Submissiondate
DIPRIVAN INJECTABLE;INJECTION propofol 019627

US Patents and Regulatory Information for DIPRIVAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fresenius Kabi Usa DIPRIVAN propofol INJECTABLE;INJECTION 019627-001 Oct 2, 1989 DISCN No No   Start Trial   Start Trial   Start Trial
Fresenius Kabi Usa DIPRIVAN propofol INJECTABLE;INJECTION 019627-002 Jun 11, 1996 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for DIPRIVAN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Fresenius Kabi Usa DIPRIVAN propofol INJECTABLE;INJECTION 019627-002 Jun 11, 1996   Start Trial   Start Trial
Fresenius Kabi Usa DIPRIVAN propofol INJECTABLE;INJECTION 019627-002 Jun 11, 1996   Start Trial   Start Trial
Fresenius Kabi Usa DIPRIVAN propofol INJECTABLE;INJECTION 019627-002 Jun 11, 1996   Start Trial   Start Trial
Fresenius Kabi Usa DIPRIVAN propofol INJECTABLE;INJECTION 019627-002 Jun 11, 1996   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
McKinsey
McKesson
Medtronic
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.